
# Variation of Site-Specific Glycosylation Profiles for Influenza Glycoproteins from Different Sources

Zachary Goecker, Meghan Burke, Concepcion Remoroza, Yi Liu, Yuri Mirokhin, Sergey Sheetlin, Dmitrii Tchekhovskoi, Xiaoyu Yang, and Stephen Stein

# BMD Staff Seminar

May 17, 2022











# Why Glycopeptides at NIST?

- Tandem libraries are growing.
- Glycopeptides prominent in biologics.
- Measurement of glycosylation is difficult and hard to reproduce.
- Variation in glycosylation pattern unknown. How reproducible?








# Influenza Virus

- 10 proteins
- Hemagglutinin (HA) and neuraminidase (NA) transmembrane proteins.
- Diversity of strains arise through two mechanisms: point mutations in the viral genome or reassortment between two co-circulating strains.







### Influenza Vaccine

- Quadrivalent: 4 strains
  - 2 Influenza A strains
  - 2 Influenza B strains
- Embryonated chicken eggs
- Inactivated by rupturing membrane
- Adjuvants

Influenza A (H3N2)







Influenza A (H1N1)


Influenza B (Victoria)

Influenza B (Yamagata)










#### NIST


**Material Measurement Laboratory** 

Why Glycosylation Matters For Vaccines

...THLNF<mark>K</mark>YPAL... ...THLNF<mark>T</mark>YPAL... Sequon motif NXT/S X≠P



NIST




NIST



### Methods – Data Processing

- 1. Glycopeptide search using Byonic software
- Tandem library creation and spectral validation via create\_glycopeptide\_lib.exe and MS\_Piano.exe.
- 3. GADS creation using makegads.exe


<u>G</u>lycopeptide <u>A</u>bundance <u>D</u>istribution <u>Spectrum</u>






# Variation in glycosylation profile - Replicate

#### **Biological Replicate**



Protein	Sequon	Average match score
Hemagglutinin	39	980 ± 2
	170	913 ± 60
	181	968 ± 16
	302	884 ± 92
	500	884 ± 27
Neuraminidase	68	973 ± 6
	126	945 ± 21
	215	959 ± 11
Total		939 ± 62

#### **Technical Replicate**




Protein	Sequon	Average match score
Hemagglutinin	39	963
	170	967
	181	939 ± 40
	302	946 ± 44
	500	926 ± 27
	68	939 ± 14
Neuraminidase	126	961 ± 24
	215	927 ± 68
Total		946 ± 38




# Variation in glycosylation profile - Lot

#### **Batch Variation**



Protein	Sequon	Average match score
Hemagglutinin	39	889 ± 75
	170	843 ± 38
	181	942 ± 19
	302	909 ± 45
	500	872 ± 69
Total		897 ± 57

#### Lot Variation




Protein	Sequon	Average match score
	68	903 ± 39
Neuraminidase	126	852 ± 72
	215	910 ± 48
Total		891 ± 57



# Variation in glycosylation profile - Proteases

- Trypsin + Lys-C
- Trypsin + Glu-C
- Trypsin + Chymotrypsin
- Chymotrypsin + Glu-C
- Chymotrypsin
- Alphalytic protease

Average match: 819 ± 106






# Variation in glycosylation profile - Vendor

#### <u>Vendors</u>

- BioVision
- Sino Biological
- US Biological



#### **Cumulative Glycopeptide Match Scores**


#### <u>Strains</u>

- HA (A/Hong Kong/483/1997) H5N1
- NA (A/Thailand/1(KAN-1)/2004) H5N1

Average match score: 638 ± 218



## Variation in glycosylation profile – Same Strain





### Variation in glycosylation profile – Different Strains


Protein	Strain	Subtype	Number of sequons	Protein mass* (kDa)
HA	A/California/04/2009	H1N1	8	63
NA	A/California/04/2009	H1N1	8	52
HA	A/Hong Kong/483/1997	H5N1	8	64
HA	A/Hong Kong/485197/2014	H3N2	13	64
HA	A/Japan/305/1957	H2N2	8	63
HA	A/New Caledonia/20/1999	H1N1	10	63
NA	A/Arizona/13/2008	H1N1	9	52
NA	A/Netherlands/219/2003	H7N7	11	52
NA	A/Thailand/1(KAN-1)/2004	H5N1	3	49
				*Unglycosylated

#### Average Match Score: 463 ± 130

#### B/Victoria/705/2018 B/Phuket/3073/2013

A/Philippines/2/1982(H3N2) A/Cambodia/e0826360/2020(H3N2) A/Switzerland/NIB88/2013(H3N2) A/HongKong/485197/2014(H3N2) A/NewCaledonia/20/1999(H1N1) A/Victoria/2570/2019(H1N1) A/California/04/2009(H1N1) A/HongKong/483/1997(H5N1) A/Japan/305-/1957(H2N2) 

# Summary of Variation



#### Sources of Variation in GADS


- Glycosylation of replicates is most similar and between strains is least similar.
- More deviation associated with lower match scores.
- "Random" is measured between different proteins from different vendors. (A1AG vs HA)



### Isolation of Adjacent Sequons

- Site-specific glycosylation methods require a single sequon per peptide. Different proteases are used to maximize isolation.
- Influenza, HIV, Ebola, Herpesvirus, and MERS have adjacent sequons


NXT/S X≠P NNSS, NNTT, NNST, NNTS






# Isolation of Adjacent Sequons - EThcD

- ETD (Electron Transfer Dissociation)
- HCD (High-Energy Collisional Dissociation)




# Isolation of Adjacent Sequons - EThcD

- ETD (Electron Transfer Dissociation)
- HCD (High-Energy Collisional Dissociation)



## Isolation of Adjacent Sequons - Subtilisin

• Bacillus subtilis – extracellular serine endopeptidases





DQICIGYHAn ???




# Next Steps: Influenza Vaccines

- Afluria Quadrivalent
  - Split virion
  - 60 mg HA per dose (15 mg per strain)
  - Thimerosal
  - Mercury
  - Sodium Chloride
  - Sodium Phosphate
  - Potassium Phosphate
  - Potassium Chloride
  - Calcium Chloride
  - Sodium Taurodeoxycholate
  - Ovalbumin
  - Sucrose.....
- 67 sequons within all HA and NA proteins










### Influenza Vaccines – Challenges and Solutions

MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTT	VWCASGRSKVIKGSLPLIGEADCLHEKYGGINKSKPYYTGEHAKAIGNCPIWVKT-PL
MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTT	VWCASGRSKVIKGSLPLIGEADCLHEEYGGINKSKPYYTGKHAKAIGNCPIWVKT-PL
MKAILVVMLYTFTTANADTLCIGYHANNSTDTVDTVLEKNVT/THSVNLLE	AFTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTSLPF-QNVHPITIGKCPKYVKSTKL
MKTIIALSYILCLVFAQKIPGNDNSTATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQ	YFKIR-SGKSSIMRSDAPIGKCKSECITFNGSIPNDKPF-QNVNRITYGACPRYVKQSTL
**:*:.: .: ** * : . *.* * : . *.* *	:*::*: *: *: *: *: *: *: *: ** **
TPTKSHFANLKGTETRGKLCPKCLNCTDLDVALSRPKCTGKIPSARVSILH-EVRPVTSG	KLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQ
TPTKSYFANLKGTRTRGKLCPDCLNCTDLDVALGRPMCVGTTPSAKASILH-EVRPVTSG	KLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQ
DKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTARSWSYIVETSNSDNGT	RLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQ
NSSIGEICDSPH-QILDGGNCTLIDALLGDPQCDGFQN-KEWDLFVERSR-ANSN	KLATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQ
	:**.* : * : * : **:******
CFPIMHD-RTKIRQLPNLLRGYEHVRLSTHNVINAEDAPGGPYEIGTSGSCPNITNGNGF	EAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLL
CFPIMHD-RTKIRQLPNLLRGYEKIRLSTQNVIDAEKAPGGPYRLGTSGSCPNATSKIGF	EAINKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLL
CYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAACPHAG-AKSF	NAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLL
CYPYDVPDYASLRSLVASSGTLEFKNESFNWTGV-KQNGTSSACIRGS-SSSF	AAIDQINGKLNRLIGKTNEKFHQIEKEFSEVEGRVQDLEKYVEDTKIDLWSYNAELLVAL
*:* .:*: .: .: .: .: .: .: .: .:	**::*. ::* : :: :: ::::: *:* * * :: ** * *
FATMAWAVPKNKTATNPLTIEVPYICTEGEDQITVWGFHSDNEIQ-MAKLYGDSKPQK	SNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKONOTCLDRIAAGTFDAGEF
FATMAWAVPKDNYKNATNPLTVEVPYICTEGEDQITVWGFHSDNKTQ-MKSLYGDSNPQK	SNEGIINSEDEHLLALERKLKKMLGPSAVDIGNGCFETKHKONOTCLDRIAAGTFNAGEF
YKNLIWLVKKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIADQQSLYQNADAYV	ENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKY
FSRLNWLTHLNYTYPALNVTMPNNEQFDKLYIWGVHHPSTDKDQISLFAQPSGRI	ENQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIFNETYDHNVY
: : *	.*: :: *: * .* :: * .* ::*****
FTSSANGVTTHYVSQIGGFF <mark>NQT</mark> EDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQK	SLPTFDS-INITAASLNDDGLDNHTILLYYSTAASSLAVTLMIAIFVVYMVSRDSVSCSI
FTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPGKTGTIVYQRGVLLPQK	SLPTFDS-INITAASLNDDGLDNHTILLYYSTAASSLAVTLMLAIFIVYMVSRDNVSCSI
FVG-TSRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVAPRY	SEEAKLNREKIDGVKLDSTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRI
TVS-TKRSQQAVIPNIGSRPRIRDIPSRISIYWTIVKPGDILLINSTGNLIAPRG	RDEALNNRFQIKGVELKSGYKDWILWI-SFAMSCFLLCIALLGFIMWACQKGNIRCNI
:. :*. **: ::: *. : .:: *:	: . :** ** * . *.::::::::::::::



### Afluria GADS


- ~8 of the 40 sequons for the four hemagglutinin proteins identified.
- The GADS are majority high-mannose.
- No GADS were identified for NA proteins, probably due to a lower abundance of NA on the virus.





### Afluria GADS

- ~8 of the 40 sequons for the four hemagglutinin proteins identified.
- The GADS are majority high-mannose.
- No GADS were identified for NA proteins, probably due to a lower abundance of NA on the virus.





### Conclusions

- Glycosylation of replicates is most similar and between strains is least similar.
- Adjacent sequons may be isolated using EThcD fragmentation or nonspecific cleavage using the protease subtilisin.
- Most glycans are high-mannose in egg-based quadrivalent vaccines.
- Next steps:
  - Optimize methods for influenza vaccine digestion.
  - Build reference MS2 and GADS libraries
  - Apply methods to other viral glycoproteins (HIV, Herpesvirus, Ebola...)



# Acknowledgments

#### <u>Software</u>

- Yuri Mirokhin
- Sergey Sheetlin
- Dmitrii Tchekhovskoi
- Xiaoyu Yang
- Guanghui Wang
- Stephen Stein

#### Lab mentoring

- Yi Liu
- Jane Zhang

#### Data acquisition/analysis

- Meghan Burke Harris
- Connie Remoroza



References

<sup>1</sup>Jung, H. E., & Lee, H. K. (2020). Host protective immune responses against influenza A virus infection. *Viruses*, *12*(5), 504.

<sup>2</sup>Remoroza, C. A., Burke, M. C., Liu, Y., Mirokhin, Y. A., Tchekhovskoi, D. V., Yang, X., & Stein, S. E. (2021). Representing and Comparing Site-Specific Glycan Abundance Distributions of Glycoproteins. Journal of Proteome Research, 20(9), 4475-4486.

<sup>3</sup>https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm

<sup>4</sup>Zost, S. J., Parkhouse, K., Gumina, M. E., Kim, K., Perez, S. D., Wilson, P. C., ... & Hensley, S. E. (2017). Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by eggadapted vaccine strains. *Proceedings of the National Academy of Sciences*, *114*(47), 12578-12583.

Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., & Crispin, M. (2020). Site-specific glycan analysis of the SARS-CoV-2 spike. Science, 369(6501), 330-333.

Chang, D., & Zaia, J. (2019). Why glycosylation matters in building a better flu vaccine. Molecular & Cellular Proteomics, 18(12), 2348-2358.





zachary.goecker@nist.gov



### Supplemental Slides


**Dot Product** 

Cosine of the angle between spectra represented as vectors

 $\frac{(\Sigma W_L W_U)^2}{\Sigma W_L^2 \Sigma W_U^2}$ 

 $W_L$  = Weighted intensity of library

 $W_{II}$  = Weighted intensity of unknown



**Figure 1.** Vector representation of a hypothetical three-peak unknown (U) and library (L) mass spectrum in three-dimensional space (peaks have mass M1, M2, and M3).





Figure 2. Point representation of library search results (L) for a hypothetical three-peak unknown (U) spectrum (masses M1, M2, and M3)



# Supplemental Slides

# Glycobiology

- In viruses
  - Immune evasion
  - Host cell attachment
- In mammalian cells
  - Protein folding
  - Protein stabilization
  - Communication
  - Function






## Supplemental Slides

#### Vendor Comparison


Glycan distribution was skewed toward higher mass (sialylated complex) glycans for vendor 2 and toward lower mass glycans (oligomannose and hybrid) for vendor 1 and vendor 3.







#### Material Measurement Laboratory







#### Stepped HCD



ETD

EThcD

**EThcD** 



### Supplemental Slides

CID/HCD